In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

Rudalska, Ramona, Dauch, Daniel, Longerich, Thomas, McJunkin, Katherine, Wuestefeld, Torsten, Kang, Tae-Won, Hohmeyer, Anja, Pesic, Marina +13 more·2014·Nature Medicine
DOI 10.1038/nm.3679

Cited by (284)

Items 201–284 of 284

  1. Exploiting lipotoxicity for the treatment of liver cancer
    Ramona Rudalska, Lars Zender, Daniel Dauch · 2021 · British Journal of Cancer
  2. Are we ready for targeted therapy combinations in HCC?
    Einat Cinnamon, Eli Pikarsky · 2020 · Gut
  3. Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform
    Katarzyna Jastrzebski, Bastiaan Evers, Roderick L. Beijersbergen · 2016 · Methods in molecular biology
  4. IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma
    Xiaoxiao Li, Fujia Lu, Jie Zhou, Xiong Li, Yan Li, Weijie Ye, Jing Li, Liguo Yang, Shi Jie Tang, Yuhan Zhou et al. · 2025 · Cell Death and Disease
  5. Tumor evolution-targeted nanomedicineEVT
    Lingpu Zhang, Jia‐Zhen Yang, Dongsheng Tang, Hanchen Zhang, Jianxun Ding, Haihua Xiao · 2022 · Scientia Sinica Chimica
  6. Advances in Making Cancer Mouse Models More Accessible and Informative through Non-Germline Genetic Engineering
    Katherine C. Murphy, Marcus A. Ruscetti · 2023 · Cold Spring Harbor Perspectives in Medicine
  7. The search for precision models clinically relevant to human liver cancer.
    Wen Xue, Xin-Wei Wang · 2015 · Hepatic Oncology
  8. Clinical value of identifying genes that inhibit hepatocellular carcinomas
    Ugo Testa, Elvira Pelosi, Germana Castelli · 2022 · Expert Review of Molecular Diagnostics
  9. Molecular diagnostics of hepatobiliary and pancreatic neoplasias
    Thomas Longerich, Albrecht Stenzinger, Peter Schirmacher · 2024 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  10. A stress-responsive p38 signaling axis in choanoflagellates
    Florentine U. Rutaganira, Maxwell C. Coyle, Maria H. T. Nguyen, Iliana Hernandez, Alex P. Scopton, Arvin C. Dar, Nicole King · 2025 · RSC Chemical Biology
  11. A cross-omics approach to investigate temporal gene expression regulation by 5-hydroxymethylcytosine via TBH-derived oxidative stress showed involvement of different regulatory kinases
    Jacob J. Briedé, Lize Deferme, Jarno E.J. Wolters, Sandra M.H. Claessen, Twan van den Beucken, J. Richard Wagner, Simone G. J. Van Breda, Jos C. S. Kleinjans · 2018 · Toxicology in Vitro
  12. Identification of circular RNA biomarkers for Pien Tze Huang treatment of CCl4‑induced liver fibrosis using RNA‑sequencing
    Ting Wang, Jinhang Zhu, Long‐Hui Gao, Muyun Wei, Di Zhang, Luan Chen, Hao Wu, Jingsong Ma, Lixing Li, Na Zhang et al. · 2022 · Molecular Medicine Reports
  13. MYBPC1 is a key regulator for laryngeal carcinoma formation
    Jing Liu, Jinlan Song, Chao Li · 2022 · Anti-Cancer Drugs
  14. Emerging Role of the Pathologist in Precision Medicine for HCC
    Thomas Longerich, Peter Schirmacher · 2019 · Digestive Diseases and Sciences
  15. Hepatocellular Carcinoma
    Rahmat Adetutu Adisa, Lateef Adegboyega Sulaimon · 2022 · IntechOpen eBooks
  16. Advance on the effects of algal carotenoids on inflammatory signaling pathways
    Yudi Wang, Xinrong Geng, Song Qin, Tuanjie Che, Libo Yan, Biao Yuan, Wenjun Li · 2024 · European Journal of Medicinal Chemistry
  17. In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling
    Yu Tian, Xin Bao, Shan Lei, Youcai Huang, Xiaoling Wang, Yanyang Tu, Qinglian He, Feixiang Zhang, Haicheng Xu, Milad Ashrafizadeh et al. · 2025 · Cell Communication and Signaling
  18. A Transposon-Based Mouse Model of Hepatocellular Carcinoma via Hydrodynamic Tail Vein Injection
    Sijia Yu, Santiago Vernia · 2020 · Methods in molecular biology
  19. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists
    Su Jin Lee, Ho Yeong Lim · 2017 · Expert Opinion on Emerging Drugs
  20. Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic
    Yunxi Liu, Yue Chen, Weidong Fei, Caihong Zheng, Yongquan Zheng, Miao Tang, Ying Qian, Xiao Zhang, Mengdan Zhao, Meng Zhang et al. · 2021 · Frontiers in Bioengineering and Biotechnology
  21. Low-temperature plasma-activated medium enhances the chemosensitivity of colorectal cancer cells by improving hypoxia.
    Yanming Xu, Ying Li, Xiaodong Yang, Dehua Lu, Yuanyuan Zheng, Jingyun Tan, Wenhua Li, Qi Chen, Ya Jie Liu, Jing Gao et al. · 2023 · PubMed Central
  22. Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator
    Jean‐Charles Nault · 2017 · Gastroenterology
  23. Incapacitated Capicua in Sorafenib-Resistant HCC
    Dingzi Yin, Kirk J. Wangensteen · 2020 · Cellular and Molecular Gastroenterology and Hepatology
  24. Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling
    Michael Förster, Heike K. Wentsch, Stefan Laufer · 2021 · Organic Process Research & Development
  25. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review
    K. Menshikov, A. Sultanbaev, S. Musin, I. R. Rakhmatullina, I. A. Menshikova, R. R. Abdeev, N. Sultanbaeva, E. Popova, G. A. Serebrennikov · 2022 · Creative Surgery and Oncology
  26. [Role and mechanism of Galectin-3 gene in proliferation, invasion, and apoptosis of oral squamous cell carcinoma].
    Zheng Dong Fang, Feng Qiu, Junfang Zhao, Qiang Sun, Bin Qiao, Guanghui Li, Xinming Li · 2018 · PubMed Central
  27. An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes
    Eric K. Hubner, Christian Lechler, Birgit Kohnke‐Ertel, Anne‐Flore Zmoos, Julien Sage, Roland Michael Schmid, Ursula Ehmer · 2016 · The Journal of Gene Medicine
  28. Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma
    Chiun Hsu, Ann‐Lii Cheng · 2017 · Resistance to targeted anti-cancer therapeutics
  29. ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR‐548p/TUFT1 axis
    Zhenjie Li, Jinping Zhang, Dongying Li, Huiyu Yang, Bing-Rong Liu · 2021 · Hepatology Research
  30. Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma
    Weihua Song, Meng Li, Wangrui Liu, Wenhao Xu, Hongyun Zhou, Shiyin Wei, Jiachang Chi · 2025 · Clinical and Experimental Medicine
  31. Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one MKK4 Inhibitor
    Leon Katzengruber, Pascal Sander, Stefan Zwirner, Alexander Rasch, Eric Eberlein, Roland Selig, Wolfgang Albrecht, Lars Zender, Stefan Laufer · 2025 · Journal of Medicinal Chemistry
  32. Comment on “combination treatment including targeted therapy for advanced hepatocellular carcinoma”
    Lijun Zhang, Guangming Li · 2016 · HepatoBiliary Surgery and Nutrition
  33. Fluorescence-Reporting-Guided Tumor Acidic Environment-Activated Triple Photodynamic, Chemodynamic, and Chemotherapeutic Reactions for Efficient Hepatocellular Carcinoma Cell Ablation
    Mengyu Yao, Xiaojie Wang, Kunshan Huang, Xiao Jia, Jinping Xue, Bing Guo, Juanjuan Chen · 2022 · Langmuir
  34. Sorafenib resistance uncovered by novel RNAi screen
    Lisa Hutchinson · 2014 · Nature Reviews Clinical Oncology
  35. Next Generation of Preclinical Liver Cancer Models
    A. Weber, Tracy O'Connor, M. Heikenwalder · 2015 · Clinical Cancer Research
  36. Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38α MAPK/PDE-4 Inhibitors for Treatment of TNFα-Driven Diseases
    Wolfgang Albrecht, S. M. Bauer, Stefan Laufer · 2017 · Elsevier eBooks
  37. Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma
    Hongbo Ni, Jian Xue, Fan Wang, Xiaohan Sun, Meng Niu · 2021 · Journal of Biomedical Nanotechnology
  38. Biological Networks Governing the Acquisition, Maintenance, and Dissolution of Pluripotency: Insights from Functional Genomics Approaches
    Kevin Andrew Uy Gonzales, Huck‐Hui Ng · 2015 · Cold Spring Harbor Symposia on Quantitative Biology
  39. Targeting of non-oncogene addiction
    Ana Igea, J. R. P. Gupta, Ángel R. Nebreda · 2015 · Aging
  40. Mechanisms of Reversible Sorafenib Resistance in Hepatocellular Carcinoma
    Elizabeth A. Kuczynski · 2016 · TSpace (University of Toronto)
  41. Integrated combinatorial functional genomics and spatial transcriptomics of tumors decodes genotype to phenotype relationships
    Marco Breinig, Artem Lomakin, Elyas Heidari, Michael A. Ritter, Gleb D. Rukhovich, Lio Böse, Luise Butthof, Lena Wendler-Link, Hendrik Wiethoff, Tanja Poth et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Multi-omics of sorafenib responsiveness in HCC patients
    Eva Dazert, Tuyana Boldanova, Charlotte K.Y. Ng, Marco Colombi, Stefan F. Wieland, George Rosenberger, Francesco Marass, Salvatore Piscuoglio, Niko Beerenwinkel, Luigi Terracciano et al. · 2025 · medRxiv
  43. Intracellular magnetic hyperthermia reverses sorafenib resistance in hepatocellular carcinoma through its action on signaling pathways
    Hugang Li, Zirui Ye, Xun Wang, Jianlan Yuan, Jingyi Guo, Chen Liu, Bin Yan, Haiming Fan, Yi Lyu, Xiaoli Liu · 2024 · iScience
  44. Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation
    Qiong Zhou, Rui Wang · 2025 · Frontiers in Pharmacology
  45. The Stress Kinase p38a as a Target for Cancer Therapy
    Ana Igea, Ángel R. Nebreda · 2015
  46. Hepatitis B Virus-Induced Resistance to Sorafenib and Lenvatinib in Hepatocellular Carcinoma Cells: Implications for Cell Viability and Signaling Pathways
    Narmen Esmael, Ido Lubin, Ran Tur‐Kaspa, Romy R. Zemel · 2024 · Cancers
  47. A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration
    Masahiro Hayashi, Tetsuhiro Chiba, Sadahisa Ogasawara, Yoshihiko Ooka, Eiichiro Suzuki, Tomoko Saito, Naoya Kanogawa, Akinobu Tawada, Masayuki Otsuka, Masaru Miyazaki et al. · 2015 · Kanzo
  48. Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
    Athina Anastasia Moschopoulou, Stefan Zwirner, Lars Zender, Daniel Dauch · 2020 · Topics in medicinal chemistry
  49. Modelling liver cancer microenvironment: novel 3D culture system as a potential anti-cancer drug screening tool
    Ala’a Al Hrout, Karla Cervantes-Gracia, Richard Chahwan, Amr Amin · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  50. Global Approaches to Understanding Protein Kinase Functions
    Jennifer L. Gorman, James Robert Woodgett · 2015 · Wiley eBooks
  51. The interaction between Hedgehog/Patched and Ras signaling in Rhabdomyosarcoma
    Nicole Cuvelier · 2016
  52. Targeted Therapy for Hepatocellular Carcinoma: What`s New?
    Haluk Yuzugullu, Özge Gürsoy-Yüzügüllü · 2015 · Liver Research - Open Journal
  53. Overcoming Treatment Resistance in Hepatocellular Carcinoma: Regorafenib and Lessons from Other Malignancies
    Bingnan Zhang, Richard S. Finn · 2017 · Resistance to targeted anti-cancer therapeutics
  54. Molecular Classification of Hepatocellular Carcinoma and Precision Medicine
    Michael Feely · 2017 · Molecular pathology library
  55. Heilen mittels Wirkstoff-Recycling
    Dagmar Kraus · 2018 · CME
  56. Das hepatozelluläre Karzinom – pathologische und molekularpathologische Diagnostik
    Peter Schirmacher · 2018 · Der Onkologe
  57. Deciphering mechanisms of response and resistance in large-scale mouse cancer screens
    Anirudh Prahallad, Michael Rugaard Jensen, Emilie A. Chapeau · 2019 · Current Opinion in Genetics & Development
  58. Targeting mutant KRAS in pancreatic cancer
    Tikvah K. Hayes · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  59. Generation of Mouse Models of Cancer Using Transposon‐Mediated Approaches
    Camino Bermejo‐Rodríguez, Pedro Antonio Pérez-Mancera · 2017 · Encyclopedia of Life Sciences
  60. TARGETING THE ERK MAPK PATHWAY IN RAS-DRIVEN CANCERS
    Meagan B. Ryan · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  61. In vivo animal models for cancer: What have we learned from chemical-induced and xenograft models
    Sanyog Jain, Kaisar Raza, Ashish Kumar Agrawal, Ankur Vaidya · 2020 · Elsevier eBooks
  62. PLEKHG5, Stabilized by HDAC2-Related Deacetylation, Confers Sorafenib Resistance Through Regulating Rac1/AKT/NF-κB Signaling in HCC
    Yu Sha, Mingang Pan, Liangjun Qiao, Hengyu Zhou, Yunmeng Chen, Ying Cai, Dina Liu, Wenlu Zhang, Kai Wang, Luyi Huang et al. · 2021 · SSRN Electronic Journal
  63. Precision medicine approaches for treating hepatocellular carcinoma
    Nadia Ahmed, Kevin Benny, Sohail Siraj, Hufsa Ali, Riyaz M. Basha · 2022 · Elsevier eBooks
  64. Malignant liver tumors
    Islam B. Mohamed, Ahmed El Sabagh, Fuad ZainAloor, Mohamed El Talkhan, Zahraa Al lami, Megha Bhongade, Shilpa Jain, Prasun K. Jalal · 2024 · Elsevier eBooks
  65. SRChing for new targets in HCC
    Michael T. Dill, Jan S. Tchorz · 2025 · Hepatology
  66. In vivo RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer
    Inga Hochnadel, Lisa Hoenicke, Nataliia Petriv, Huizhen Suo, Lothar Groebe, Chantal Olijnik, Н. С. Бондаренко, Juan Carlos López Alfonso, Michael Jarek, Ruibing Shi et al. · 2025 · Frontiers in Immunology
  67. Low-Dose Celastrol Modulates IL-6 Secretion to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
    Rui Zhang, Lingchun Kong, Hezhao Zhang, Anhong Zhang, Zhiyong Shi, Pei Wei · 2025 · Iranian journal of pharmaceutical research
  68. A Warm Welcome to MedChem: The Frontiers in Medicinal Chemistry 2025
    Matthias Schiedel, Marta Pinto, Andrea Unzue Lopez, Philipp Barbie, Felix Pape, Anika Tarasewicz, Gerhard Heßler, Peter Gmeiner, Christina Lamers, Matthias Gehringer · 2025 · ChemMedChem
  69. The Functions and Regulatory Chemicals of Human Leucine Zipper Transcription Factors (LZ TFs)
    Hanming Yang, Shuyang Bi, Biao Yu, Pengfei Fang, Jing Wang · 2025 · 化学学报
  70. Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening
    Jingyi Jiang, Zihua Jiang, Qian Luo, Xi Chen, Jiejie Zhuang, Jiaxin Chen, Qingqing Mu, Jin Qiu, Yan Li, Shuxia Chen et al. · 2025 · Cell Death and Disease
  71. Targeting p38α in cancer: challenges, opportunities, and emerging strategies
    Ángel R. Nebreda · 2026 · Molecular Oncology
  72. EVALUATION DE L’INHIBITION DE L’ANGIOGENESE DANS LE NEUROBLASTOME ET CARACTERISATION DE MECANISMES DE RESISTANCE
    Estelle Daudigeos‐Dubus · 2014
  73. Un analogue de synthèse de la squalamine, NV669, comme nouvel inhibiteur de la protéine Tyrosine Phosphatase 1B (PTP1B) : étude de ses effets in vitro et in vivo sur la croissance des tumeurs pancréatiques et hépatiques
    Sylvie Carmona · 2017
  74. Mécanismes moléculaires de la tumorigénicité induite par l'isoforme A du récepteur de l'insuline dans les cellules de carcinome hépatocellulaire
    Eva Benabou · 2017
  75. Evaluating the landscape of gene cooperativity with RTKs in liver tumorigenesis and its evolution
    Sehrish Khan Bazai · 2020
  76. Dynamical modelling of the RAS-RAF-MEK-ERK pathway in the hepatocellular cells exposed to sorafenib
    Anne‐Sophie Giacobbi · 2019
  77. Outcome of liver transplantation for hepatocellular carcinoma within and beyond Milan criteria
    Mohamed Gomaa Mourad · 2019 · theses.fr (ABES)
  78. Modèle de carcinomes hépatocellulaires murins induits par l'expression de l'antigène T SV40 : analyse du transcriptome entier du foie et des variations d'expression ARN liées à l'âge et induites par un régime « occidental »
    Christian Hobeika · 2022 · theses.fr (ABES)
  79. Stratégies thérapeutiques compensatoires en cas de perte de fonction du récepteur de peptides formylés 1
    Julie Le Naour · 2022
  80. Integrated immunogenomic analysis exploring tumor heterogeneity and evolution of hepatocellular carcinoma
    Long Pan · 2024
  81. Stéatopathie métabolique et carcinome hépatocellulaire : prédiction de la carcinogenèse à la réponse au traitement par profilage protéomique
    Adèle Delamarre · 2024
  82. Loss of cBAF Complex Confers Sorafenib Resistance in Liver Cancer
    Jacqueline A. Brinkman, Margarita M. Dzama, Max Bucklan, Carl J. Manner, Mallory Sokolowski, Jesse R. Raab · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  83. BindingDB Entry 50000338: Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
    BindingDB · 2019 · UC San Diego
  84. BindingDB Entry 50015201: Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors.
    BindingDB · 2023 · UC San Diego